Details
Stereochemistry | RACEMIC |
Molecular Formula | C3H2ClF5O |
Molecular Weight | 184.492 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)OC(F)(F)C(F)Cl
InChI
InChIKey=JPGQOUSTVILISH-UHFFFAOYSA-N
InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H
Molecular Formula | C3H2ClF5O |
Molecular Weight | 184.492 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Enflurane (2-chloro-1,1,2,-trifluoroethyl-difluoromethyl ether) is a halogenated ether structural isomer of isoflurane. Developed by Ross Terrell in 1963, it was first used clinically in 1966. It was increasingly used for inhalational anesthesia during the 1970s and 1980s but is no longer in common use. Clinically, enflurane produces a dose-related depression of myocardial contractility with an associated decrease in myocardial oxygen consumption. Between 2% and 5% of the inhaled dose is oxidized in the liver, producing fluoride ions and difluoromethoxy-difluoroacetic acid. This is significantly higher than the metabolism of its structural isomer isoflurane. The exact mechanism of the action of general anesthetics has not been delineated. Enflurane acts as a positive allosteric modulator of the GABAA, glycine, and 5-HT3 receptors, and as a negative allosteric modulator of the AMPA, kainate, and NMDA receptors, as well as of nicotinic acetylcholine receptors.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3392921 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16973644 |
|||
Target ID: CHEMBL2096670 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7681790 |
|||
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7681790 |
|||
Target ID: CHEMBL2109241 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7681790 |
|||
Target ID: CHEMBL2094107 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16973644 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ETHRANE Approved UseINDICATIONS AND USAGE. ĒTHRANE (enflurane, USP) may be used for induction and maintenance of general anesthesia. Enflurane may be used to provide analgesia for vaginal delivery. Low concentrations of enflurane (see DOSAGE AND ADMINISTRATION) may also be used to supplement other general anesthetic agents during delivery by Cesarean section. Higher concentrations of enflurane may produce uterine relaxation and an increase in uterine bleeding. Launch Date8.3808002E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15 μg/mL |
2 % single, respiratory dose: 2 % route of administration: Respiratory experiment type: SINGLE co-administered: |
ENFLURANE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
60 min |
2 % single, respiratory dose: 2 % route of administration: Respiratory experiment type: SINGLE co-administered: |
ENFLURANE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
4 % single, respiratory |
unhealthy, 25 years n = 1 Health Status: unhealthy Condition: cholecystitis Age Group: 25 years Sex: F Population Size: 1 Sources: |
Disc. AE: Malignant hyperthermia... AEs leading to discontinuation/dose reduction: Malignant hyperthermia Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Malignant hyperthermia | Disc. AE | 4 % single, respiratory |
unhealthy, 25 years n = 1 Health Status: unhealthy Condition: cholecystitis Age Group: 25 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
The relationship of brain catecholamine levels to enflurane requirements among three strains of mice with different anesthetic sensitivities. | 2001 |
|
Volatile general anesthetics reveal a neurobiological role for the white and brown genes of Drosophila melanogaster. | 2001 Dec |
|
Gender-related plasma levels of progesterone, interleukin-8 and interleukin-10 during and after cardiopulmonary bypass in infants and children. | 2001 Dec |
|
[Alcohol-xenobiotic interactions. Role of cytochrome P450 2E1]. | 2001 Nov |
|
Flumazenil improves cognitive and neuromotor emergence and attenuates shivering after halothane-, enflurane- and isoflurane-based anesthesia. | 2001 Nov |
|
Carbon monoxide production from desflurane, enflurane, halothane, isoflurane, and sevoflurane with dry soda lime. | 2001 Nov |
|
A mouse model for peripheral neuropathy produced by a partial injury of the nerve supplying the tail. | 2002 Apr 12 |
|
213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. | 2002 Apr 8 |
|
Myristate, a 14-carbon fatty acid, effectively reverses anesthesia. | 2002 Aug |
|
Effects of halothane and enflurane anesthesia on sympathetic beta-adrenoreceptor-mediated pulmonary vasodilation in chronically instrumented dogs. | 2002 Aug |
|
A second-generation blood substitute (perflubron emulsion) increases the blood solubility of modern volatile anesthetics in vitro. | 2002 Aug |
|
PKQuest: measurement of intestinal absorption and first pass metabolism - application to human ethanol pharmacokinetics. | 2002 Aug 15 |
|
An assessment of the cerebroprotective potential of volatile anaesthetics using two independent methods in an in vitro model of cerebral ischaemia. | 2002 Dec 27 |
|
[Cerebrospinal fluid shunting: anesthetic particularities]. | 2002 Feb |
|
Caudal anesthesia reduces the minimum alveolar concentration of enflurane for laryngeal mask airway removal in boys. | 2002 Feb |
|
Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. | 2002 Feb 1 |
|
The inhibitory effects of anesthetics and ethanol on substance P receptors expressed in Xenopus oocytes. | 2002 Jan |
|
Comparison of Amsorb, sodalime, and Baralyme degradation of volatile anesthetics and formation of carbon monoxide and compound a in swine in vivo. | 2002 Jan |
|
Increased lymphatic lipid transport in genetically diabetic obese rats. | 2002 Jan |
|
Pre- and postsynaptic volatile anaesthetic actions on glycinergic transmission to spinal cord motor neurons. | 2002 Jul |
|
The variable effect of low-dose volatile anaesthetics on the acute ventilatory response to hypoxia in humans: a quantitative review. | 2002 Jul |
|
The effects of drugs used in anaesthesia on platelet membrane receptors and on platelet function. | 2002 Jun |
|
The minimum local anesthetic concentration of ropivacaine for caudal analgesia in children. | 2002 Jun |
|
Degrees of aversion shown by rats and mice to different concentrations of inhalational anaesthetics. | 2002 Jun 29 |
|
Subcellular localization of trifluoroacetylated liver proteins in association with hepatitis following isoflurane. | 2002 Mar |
|
Respiratory response to skin incision during anaesthesia with infusions of propofol and alfentanil. | 2002 May |
|
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. | 2002 May 20 |
|
Experimental investigation of the behavior of gas phase simulated moving beds. | 2002 May 31 |
|
Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists. | 2002 Oct |
|
Anesthetic and ethanol effects on spontaneously opening glycine receptor channels. | 2002 Sep |
|
PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics. | 2002 Sep 26 |
|
Effect of isolation stress on anesthetic requirement in mice. | 2003 |
|
Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. | 2003 Aug 18 |
|
[Calibration of a room air gas monitor with certified reference gases]. | 2003 Dec |
|
Fluoride metabolism in smokers and non-smokers following enflurane anaesthesia. | 2003 Dec |
|
Differential interaction of anaesthetics and antiepileptic drugs with neuronal Na+ channels, Ca2+ channels, and GABA(A) receptors. | 2003 Feb |
|
Anaesthetic agents in adult day case surgery. | 2003 Jan |
|
Enflurane as an internal standard in monitoring halogenated volatile anaesthetics by headspace gas chromatography-mass spectrometry. | 2003 Jan 24 |
|
The pharmacokinetics of the interstitial space in humans. | 2003 Jul 30 |
|
[Effects of enflurane on myocardial reperfusion injury during cardiac surgery with cardiopulmonary bypass]. | 2003 Jun |
|
Cold and mechanical allodynia in both hindpaws and tail following thoracic spinal cord hemisection in rats: time courses and their correlates. | 2003 Jun 12 |
|
Volatile anesthetics regulate pulmonary vascular tension through different potassium channel subtypes in isolated rabbit lungs. | 2003 Mar |
|
Carbon monoxide production from sevoflurane breakdown: modeling of exposures under clinical conditions. | 2003 Mar |
|
Evaluation of the mass spectrometric patterns of volatile liquid anaesthetics to predict the temperature--metal caused decomposition pathway. | 2003 Mar 17 |
|
The use of a physiologically based pharmacokinetic model to evaluate deconvolution measurements of systemic absorption. | 2003 Mar 19 |
|
Enflurane decreases glutamate neurotransmission to spinal cord motor neurons by both pre- and postsynaptic actions. | 2003 May |
|
An isothermal titration calorimetry study on the binding of four volatile general anesthetics to the hydrophobic core of a four-alpha-helix bundle protein. | 2003 Nov |
|
Mutational analysis of molecular requirements for the actions of general anaesthetics at the gamma-aminobutyric acidA receptor subtype, alpha1beta2gamma2. | 2003 Nov 12 |
|
Amino acids in transmembrane domain two influence anesthetic enhancement of serotonin-3A receptor function. | 2003 Oct 21 |
|
Volatile anaesthetics induce biochemical alterations in the heme pathway in a B-lymphocyte cell line established from hepatoerythropoietic porphyria patients (LBHEP) and in mice inoculated with LBHEP cells. | 2004 Feb |
Patents
Sample Use Guides
Surgical levels of anesthesia may be maintained with 0.5 to 3.0% enflurane. Maintenance concentrations should not exceed 3.0%. If added relaxation is required, supplemental doses of muscle relaxants may be used. Ventilation to maintain the tension of carbon dioxide in arterial blood in the 35 to 45 mm Hg range is preferred. Hyperventilation should be avoided in order to minimize possible CNS excitation.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7681790
Effects of enflurane on NMDA, AMPA, and kainate-gated currents were examined in Xenopus laevis oocytes expressing mouse or human brain mRNA. Enflurane effects on the NMDA, kainate, or AMPA currents were obtained by a preincubation of enflurane alone for 60 s before a coapplication of various drugs and enflurane. Enflurane, at a clinically relevant concentration (1.8 mM), significantly inhibited both maximal and least measurable NMDA, kainate, and AMPA receptor-gated currents.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 22:22:25 UTC 2022
by
admin
on
Fri Dec 16 22:22:25 UTC 2022
|
Record UNII |
91I69L5AY5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175975
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
||
|
WHO-VATC |
QN01AB04
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
||
|
WHO-ATC |
N01AB04
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
||
|
LIVERTOX |
NBK548474
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
||
|
NDF-RT |
N0000175681
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
||
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
132998-91-5
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
SUPERSEDED | |||
|
CHEMBL1257
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
SUB06530MIG
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
3920
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | RxNorm | ||
|
ENFLURANE
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
91I69L5AY5
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
1009
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
3015
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
7909
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
115944
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
237-553-4
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
7175
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
DB00228
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
91I69L5AY5
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
13838-16-9
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
4792
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
Enflurane
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
M4905
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | Merck Index | ||
|
3226
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
1235809
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
D004737
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
DTXSID1020562
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY | |||
|
C47511
Created by
admin on Fri Dec 16 22:22:25 UTC 2022 , Edited by admin on Fri Dec 16 22:22:25 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |